273-819 mg (175-525 mg paliperidone) q 3 months corresponds to which Paliperidone palmitate formulation?

273-819 mg (175-525 mg paliperidone) q 3 months corresponds to which Paliperidone palmitate formulation?

• A. Paliperidone palmitate 1-monthly
• B. Paliperidone palmitate 3-monthly
• C. Paliperidone palmitate 6-monthly
• D. Risperidone RBP-7000

Answer: (B)

The key idea is recognizing long-acting injectable formulations and their dosing schedules. Paliperidone palmitate is available in monthly (1-monthly) form and in a longer-acting 3-monthly form, with a specific dose range per injection. A dose range of 273–819 mg palmitate given every 3 months corresponds to 175–525 mg of active paliperidone, which matches the labeling for the 3-monthly product. This formulation is commonly known as Invega Trinza. The monthly version would require injections every month, not every three months, and the six-monthly option would be a different, longer-interval product. The last choice refers to risperidone rather than paliperidone palmitate, so it does not fit the 3-monthly paliperidone schedule.

The key idea is recognizing long-acting injectable formulations and their dosing schedules. Paliperidone palmitate is available in monthly (1-monthly) form and in a longer-acting 3-monthly form, with a specific dose range per injection. A dose range of 273–819 mg palmitate given every 3 months corresponds to 175–525 mg of active paliperidone, which matches the labeling for the 3-monthly product. This formulation is commonly known as Invega Trinza. The monthly version would require injections every month, not every three months, and the six-monthly option would be a different, longer-interval product. The last choice refers to risperidone rather than paliperidone palmitate, so it does not fit the 3-monthly paliperidone schedule.